Sign up USA
Proactive Investors - Run By Investors For Investors

Cannabis stocks in Canada recover after a whirlwind week; Canopy Growth up 8.6% on Friday

Cannabis stocks stabilized in Canada on Friday after doing significant drops and bumps this week on the back of a host of news in the country that is nearing recreational legalized marijuana in Oct.
Cannabis stocks in Canada recover after a whirlwind week; Canopy Growth up 8.6% on Friday
Cannabis stocks in Canada settled after a roller-coaster week on the back of funding and acquisition announcements

Canadian cannabis stocks had a roller-coaster week, this week with extreme highs and lows but ended generally on a positive note. 

The biggest news this week was the fact that Constellation Brands (NYSE:STZ) will spend C$5bln to boost its stake in Canopy Growth Corp (CSE:WEED), sending shares up 8.6% at C$44.18 on Friday. The company reported a quarterly C$90mln net loss on Tuesday.

READ: Canopy Growth reports quarterly earnings in-line with analyst expectations; net loss of C$90.9mln

For Canopy, Constellation Brands, the New York-based beverage company, announced it will spend about C$5bn (US$3.8bn) to boost its stake in Canopy Growth, in a bet that legalization will gain traction around the world. Constellation said that it would buy 104.5 million Canopy shares priced at C$48.60 each.

“This is rocket fuel,” said chief executive officer Bruce Linton, of Canopy in an earnings calls on Wednesday. “We’re going to be way more global.”

READ: Kaneh Bosom Biotechnology: experienced management, access to capital and a clear strategy paves the way for success for the cannabis company

Other significant players in the market, including Aurora Cannabis Inc. (TSE:ACB:CA) was up 4.0%, at C$6.50 on Friday. Aphria Inc. (TSE:APH:CA) was up 1.8%, at C$10.58.

Hiku Brands (CSE:HIKU) soared 9.9% at C$2.00.

The Horizons Marijuana Life Sciences Exchange Traded Fund, a group of marijuana stocks that trades on the Toronto Stock Exchange, rose 2.80%, to C$16.55.

View full WEED profile View Profile

Canopy Growth Corporation Timeline

Related Articles

scientist in lab
August 31 2018
While the data bodes well for MTD201, Midatech is most excited by the validation of its Q-Sphera sustained release technology, which it is using in some of its other compounds
woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch
Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use